Cancer Progress 2018

 

Tuesday, May 8, 2018
7:00 – 8:00am Registration and Continental Breakfast
8:00 – 8:15am Opening Remarks
 Audio File: 
  • Jeff Bockman, PhD, Executive Vice President, Head of Oncology Practice, Defined Health
8:15 – 9:15am Keynote
Audio file: 
Laura Esserman, MD, MBA, Director, UCSF Carol Franc Buck Breast Cancer Center; Alfred A. de Lorimier Endowed Chair in General Surgery; Professor of Surgery and Radiology, UCSF
9:15 – 10:30am Cell Therapies as the New Space Race: Engineering Generation X.0
Moderator: Mike Rice, MS, MBA, Principal, Defined Health
Audio file: 
Panelists:

  • Renier Brentjens, MD, PhD, Medical Oncologists; Director, Cellular Therapeutics, Memorial Sloan Kettering Cancer Center
  • Nouhad Husseini, Head of Business Development, Regeneron Pharmaceuticals, Inc.
  • Stanley Frankel, MD, Corporate Vice President, Global Clinical R&D Hematology/Oncology, Celgene
  • Julianne Smith, PhD, Vice President, Translational Sciences, Cellectis
  • Pascal Touchon, Senior Vice President & Global Head, Cell & Gene therapy, Novartis Oncology
10:30 – 11:00am Networking Break
11:00 – 12:15pm Oncology Diagnostics – Reading the Future
Moderator: Joel Sandler, PhD, Associate Principal, Defined Health
Audio file:
Panelists:

  • Sharon Benzeno, PhD, MBA, Senior Vice President, Research and Business Development, Adaptive Biotechnologies
  • Ken Bloom, MD, President, Human Longevity
  • Lisa H. Butterfield, PhD, Professor of Medicine, Surgery, Immunology and Clinical and Translational Science; Director, Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, UPMC Hillman Cancer Center
  • Alessandra Cesano, MD, PhD, Chief Medical Officer, NanoString
  • Leora Schiff, MS, MBA, Principal, Altius Strategy Consulting, LLC
12:15 – 1:30pm Networking Luncheon
1:30 – 2:45pm Progress in Intractable Cancers- Part I – Heme Malignancies
Moderator: Mike Rice, MS, MBA, Principal, Defined Health
Audio file:
Panelists:

  • Kenneth Anderson, MD, Kraft Family Professor of Medicine, Harvard Medical School
  • Stanley Frankel, MD, Corporate Vice President, Global Clinical R&D Hematology/Oncology, Celgene
  • William Matsui, MD, Professor of Oncology, Johns Hopkins
2:45 – 4:00pm Innovative Trials & Collaborative Initiatives – Role of Patient Advocacy, Foundations & Institutes
Moderator: Jeremy Goldberg, President, JPG Healthcare LLC
Audio file: 
Panelists:

  • Lou DeGennaro, PhD, President and Chief Executive Officer, The Leukemia & Lymphoma Society
  • Lorraine Egan, President and Chief Executive Officer, Damon Runyon
  • Ramy Ibrahim, MD, Vice President, Clinical Research & Development, Parker Institute
  • T.J. Sharpe, Patient Writer, Speaker, & Patient Experience Advisor, Starfish Harbor, LLC
4:00 – 4:15pm Networking Break
4:15 – 5:30pm Value & Pricing Redux – Does the Song Remain the Same?
Moderator: Ed Saltzman, Executive Chairman, Defined Health
Audio file: 
Panelists:

  • Peter Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
  • Daniel Becker, MD, MS, Section Chief, Hematology and Oncology, VA-NYHHS; Assistant Clinical Professor of Medicine, New York University School of Medicine
  • Kapil Dhingra, MD, Managing Member, KAPital Consulting
  • Roger Longman, Chief Executive Officer, Real Endpoints
5:30 – 7:30pm Cancer Progress 2018 Reception
Wednesday, March 9, 2018
7:00 – 8:00am Continental Breakfast
8:00 – 8:15am Opening Remarks
  • Mike Rice, MS, MBA, Principal, Defined Health
Audio file: 
8:15 – 9:30am Advances in Intractable Cancers – Part II – Solid Tumors
Moderator: James Lee, PhD, Associate Principal, Oncology Lead, Defined Health
Audio file: 
Panelist:

  • Patrick Tricoli, CEO and Vice President, Corporate Development, Nanobiotix
  • David Tuveson, MD, PhD, Professor; Director of the Lustgarten Foundation Pancreatic Research Laboratory at CSHL; Director of Research for the Lustgarten Foundation
  • Denise Reinke, MS, NP, MBA, President and Chief Executive Officer, SARC
  • Wendy K.D. Selig, Founder and Chief Executive Officer, WSCollaborative, LLC
9:30 – 10:00am Networking Break
10:00 – 11:15am Innate & Adaptive Resistance to IO – Is It the TME’s Time to Shine?
Moderator: Mark Simon, Managing Director, Torreya
Audio file: 
Panelists:

  • Tom Gajewski, MD, PhD, Professor, Department of Pathology, The Ben May Department for Cancer Research, Department of Medicine- Section of Hematology/Oncology, University of Chicago
  • Llew Keltner, MD, PhD, Chief Executive Officer, Epistat
  • Timothy Reilly, PhD, DABT, Vice President, Head of Oncology Early Asset Development, Bristol-Myers Squibb
  • Robert Schneider, PhD, Associate Dean, Technology Ventures and Partnerships at NYU; Co-founder and chair of the scientific advisory board, ENB Therapeutics, NYU School of Medicine, ENB Therapeutics
  • Dmitriy Zamarin, MD, PhD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center
11:15 – 12:30pm Next Wave Antibodies and Biologics: Is IO Poised for a Sea of Change?
Moderator: Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Defined Health
Audio file:
Panelists:

  • Mike Curran, PhD, Assistant Professor, The University of Texas, MD Anderson Cancer Center
  • John Haurum, MD, DPhil, Chief Executive Officer, F-Star
  • Louis Matis, MD, Chief Development Officer, Pieris Pharmaceuticals
  • Carsten Reinhardt, MD, PhD, Chief Medical Officer, Immatics
  • Taylor Schreiber, MD, PhD, Chief Scientific Officer, Shattuck Labs, Inc.
12:30 – 1:45pm Networking Luncheon
1:45 – 3:00pm Point-Counterpoint: Cancer Progress, at the Crossroads or at a Tipping Point?
Moderator: Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Defined Health
Audio file:
Panelists:

  • John L. Cantello, PhD, Vice President, Business Development, Oncology Therapy Head, GlaxoSmithKline
  • Christoph Lengauer, PhD, Venture Partner, Third Rock Ventures
  • Brian Leyland-Jones, MBBS, PhD, Vice President, Avera Cancer Institute Center for Precision Oncology and Department of Molecular and Experimental Medicine, Avera Cancer Institute
Cancer Progress 2018 Conference Concludes